IP Library Granted Patent US 12,239,538
Granted Patent B2
US 12,239,538 · App. 17/401,843 · Granted Mar 4, 2025

System and method for treatment and prevention of periprosthetic joint infections

Inventors: Brian de Beaubien (Fenton, MI); Jude Paganelli (Coronado, CA); Daniel Pflaster (Charlotte, VT); Daivon Deans (San Diego, CA); Ryan Watson (Boulder, CO); Brian Bowman (Carlsbad, CA)
Assignee: Osteal Therapeutics, Inc.
A61F2/30724A61F2/36A61F2/389A61F2/4014A61M1/90A61F2002/3006A61F2002/30672A61F2002/30677
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,239,538
App. No.
17/401,843
Granted
Mar 4, 2025
Kind
B2
Abstract

Provided herein are rapid and effective local infection therapy methods, systems, and devices that significantly reduce the mortality, morbidity, and the cost of care in rare musculoskeletal infections. Continuous delivery of antibiotic therapy locally, at the infection site, reduces edema and provides antibiotic irrigation, significantly improving outcomes while reducing the need for systemic antibiotics.

Claims (23)

1. A spacer system for treating a patient presenting with a periprosthetic joint infection, the spacer system comprising:

a spacer configured for placement between a first implant and a second implant of a permanent joint prosthesis; and

a catheter, wherein the spacer and catheter are configured for detachable coupling;

wherein the spacer comprises:

a first surface having a convex shape configured for engagement with a corresponding concave shape of the first implant;

a second surface having a concave shape configured for engagement with a corresponding convex shape of the second implant,

an exposed surface disposed between the first surface and the second surface;

a plurality of internal channels extending within the spacer, the plurality of internal channels configured in an array about a center axis of the spacer; and

an inlet through the exposed surface that is configured to detachably couple to the catheter to receive a treatment fluid, the inlet coaxial with a first internal channel of the plurality of internal channels,

wherein the exposed surface of the spacer comprises a first plurality of outlets in fluid communication with the inlet, such that, when the spacer is implanted in the patient, treatment fluid delivered into the inlet flows into the first internal channel of the plurality of internal channels toward the center axis before exiting out through the first plurality of outlets into a joint space between the first implant and the second implant.

2. A spacer system of claim 1 , wherein the spacer system is a hip spacer system, the joint is a hip joint, the first implant is an acetabular cup, and the second implant is a femoral stem comprising a femoral head.

3. A spacer system of claim 1 , wherein the second surface of the spacer comprises a plurality of fluted channels.

4. A spacer system of claim 3 , wherein at least one of the fluted channels comprises a plurality of fluid outlets.

5. A spacer system of claim 3 , wherein the plurality of fluted channels are arrayed about the center axis of the spacer.

6. A spacer system of claim 3 , wherein, when the spacer is implanted, the plurality of fluted channels enables fluid flow under the spacer, between the spacer and the second implant.

7. A spacer system of claim 1 , wherein the spacer is undersized relative to the first implant.

8. A spacer system of claim 1 , wherein the spacer comprises a biocompatible polymer selected from the group consisting of low-density polyethylene (LDPE), high-density polyethylene (HDPE), polypropylene (PP), polyvinyl chloride (PVC) polystyrene (PS) nylon, polytetrafluoroethylene, a thermoplastic polyurethane (TPU), acetyl copolymer, silicone, polyether ether ketone (PEEK), a polyurethane, a biocompatible elastomer, and an ultrahigh molecular weight polyethylene (UHMWPE).

9. The spacer system of claim 1 , wherein the first surface comprises a second plurality of outlets in fluid communication with the inlet and the plurality of internal channels, such that, when the spacer is implanted, treatment fluid delivered into the inlet flows out through the first plurality of outlets into the joint space and out through the second plurality of outlets to the first implant.

10. The spacer system of claim 9 , wherein each internal channel of the plurality of internal channels extends within the spacer and terminates at a respective outlet of either the first plurality of outlets through the exposed surface or the second plurality of outlets through the first surface.

11. The spacer system of claim 1 , wherein the first surface is configured for articulating engagement with the first implant.

12. The spacer system of claim 11 , wherein the second surface of the spacer is configured for articulating engagement with the second implant.

13. The spacer system of claim 1 , wherein the spacer is adapted for temporary placement between said first implant and said second implant of said permanent joint prosthesis.

14. A spacer platform comprising the spacer system of claim 1 and, further comprising a pump assembly configured for coupling to the catheter.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2024
From: DE BEAUBIEN, BRIAN; PAGANELLI, JUDE; PFLASTER, DANIEL; DEANS, DAIVON; WATSON, RYAN; BOWMAN, BRIAN
To: OSTEAL THERAPEUTICS, INC.
Reel/Frame 067123/0191 →
SECURITY INTEREST Recorded Jul 1, 2022
From: OSTEAL THERAPEUTICS, INC.
To: WESTERN ALLIANCE BANK
Reel/Frame 060419/0012 →
Continuity (2)
Provisional Application 63065413 · Aug 13, 2020
Related Publication 20220047392A1 · Feb 17, 2022
References Cited (230)
US 3648294A · Shahrestani · 1972 [cited by applicant]
US 4274163A · Malcom et al. · 1981 [cited by applicant]
US 4399814A · Pratt, Jr. et al. · 1983 [cited by applicant]
US 4488549A · Lee et al. · 1984 [cited by applicant]
US 4653487A · Maale · 1987 [cited by applicant]
US 4711233A · Brown · 1987 [cited by applicant]
US 4888024A · Powlan · 1989 [cited by applicant]
US 4892550A · Huebsch · 1990 [cited by applicant]
US 5116377A · Skripitz et al. · 1992 [cited by applicant]
US 5133767A · Frey et al. · 1992 [cited by applicant]
US 5133771A · Duncan et al. · 1992 [cited by applicant]
US 5133772A · Hack et al. · 1992 [cited by applicant]
US 5156606A · Chin · 1992 [cited by applicant]
US 5290291A · Linden · 1994 [cited by applicant]
US 5340362A · Carbone · 1994 [cited by applicant]
US 5370698A · Heimke et al. · 1994 [cited by applicant]
US 5376123A · Klaue et al. · 1994 [cited by applicant]
US 5433718A · Brinker · 1995 [cited by applicant]
US 5501687A · Willert et al. · 1996 [cited by applicant]
US 5514137A · Coutts · 1996 [cited by applicant]
US 5549702A · Ries et al. · 1996 [cited by applicant]
US 5554111A · Morrey et al. · 1996 [cited by applicant]
US 5562736A · Ray et al. · 1996 [cited by applicant]
US 5571204A · Nies · 1996 [cited by applicant]
US 5618286A · Brinker · 1997 [cited by applicant]
US 5681289A · Wilcox et al. · 1997 [cited by applicant]
US 5683472A · O'Neil et al. · 1997 [cited by applicant]
US 5693099A · Harle · 1997 [cited by applicant]
US 5702446A · Schenck et al. · 1997 [cited by applicant]
US 5725596A · Burke · 1998 [cited by applicant]
US 5741265A · Chan · 1998 [cited by applicant]
US 5755811A · Tanamal et al. · 1998 [cited by applicant]
US 5827289A · Reiley et al. · 1998 [cited by applicant]
US 5871484A · Spievack et al. · 1999 [cited by applicant]
US 5916269A · Serbousek · 1999 [cited by examiner]
US 5954771A · Richelsoph et al. · 1999 [cited by applicant]
US 5980573A · Shaffner · 1999 [cited by applicant]
US 6066154A · Reiley et al. · 2000 [cited by applicant]
US 6106495A · Scott · 2000 [cited by applicant]
US 6113639A · Ray et al. · 2000 [cited by applicant]
US 6132674A · Compton et al. · 2000 [cited by applicant]
US 6155812A · Smith et al. · 2000 [cited by applicant]
US 6217619B1 · Keller · 2001 [cited by applicant]
US 6235043B1 · Reiley et al. · 2001 [cited by applicant]
US 6248110B1 · Reiley et al. · 2001 [cited by applicant]
US 6336941B1 · Subba Rao et al. · 2002 [cited by applicant]
US 6361731B1 · Smith et al. · 2002 [cited by applicant]
US 6361780B1 · Ley et al. · 2002 [cited by applicant]
US 6423083B2 · Reiley et al. · 2002 [cited by applicant]
US 6447514B1 · Stalcup et al. · 2002 [cited by applicant]
US 6544472B1 · Compton et al. · 2003 [cited by applicant]
US 6589281B2 · Hyde, Jr. · 2003 [cited by applicant]
US 6679890B2 · Margulies et al. · 2004 [cited by applicant]
US 6692529B2 · Shah · 2004 [cited by applicant]
US 6740090B1 · Cragg et al. · 2004 [cited by applicant]
US 6740120B1 · Grimes · 2004 [cited by applicant]
US 6783515B1 · Miller et al. · 2004 [cited by applicant]
US 6899716B2 · Cragg · 2005 [cited by applicant]
US 6921403B2 · Cragg et al. · 2005 [cited by applicant]
US 6942475B2 · Ensign et al. · 2005 [cited by applicant]
US 6942702B2 · Mitsugi et al. · 2005 [cited by applicant]
US 6969404B2 · Ferree · 2005 [cited by applicant]
US 6979336B2 · Durniak · 2005 [cited by applicant]
US 6981981B2 · Reiley et al. · 2006 [cited by applicant]
US 6989033B1 · Schmidt · 2006 [cited by applicant]
US 7048743B2 · Miller et al. · 2006 [cited by applicant]
US 7112205B2 · Carrison · 2006 [cited by applicant]
US 7141053B2 · Rosa et al. · 2006 [cited by applicant]
US 7141067B2 · Jones et al. · 2006 [cited by applicant]
US 7211113B2 · Zelener et al. · 2007 [cited by applicant]
US 7217260B2 · Molander et al. · 2007 [cited by applicant]
US 7250055B1 · Vanderwalle · 2007 [cited by applicant]
US 7255713B2 · Malek · 2007 [cited by applicant]
US 7300282B2 · Sapian · 2007 [cited by applicant]
US 7306629B2 · Saladino et al. · 2007 [cited by applicant]
US 7427296B2 · Evans · 2008 [cited by applicant]
US 7429346B2 · Ensign et al. · 2008 [cited by applicant]
US 7534240B1 · Johnson · 2009 [cited by applicant]
US 7572293B2 · Rhodes et al. · 2009 [cited by applicant]
US 7601157B2 · Boyd et al. · 2009 [cited by applicant]
US 7601176B2 · Soffiati et al. · 2009 [cited by applicant]
US 7641698B1 · Gibbs et al. · 2010 [cited by applicant]
US 7771428B2 · Siravo et al. · 2010 [cited by applicant]
US 7842095B2 · Klein · 2010 [cited by applicant]
US 7862619B2 · Clark · 2011 [cited by applicant]
US 7914585B2 · Keller · 2011 [cited by applicant]
US 8038682B2 · McGill et al. · 2011 [cited by applicant]
US 8097039B2 · Evans · 2012 [cited by applicant]
US 8135466B2 · Fuller et al. · 2012 [cited by applicant]
US 8366782B2 · Wright · 2013 [cited by applicant]
US 8388881B2 · Giori · 2013 [cited by applicant]
US 8454706B2 · de Beaubien · 2013 [cited by applicant]
US 8475505B2 · Nebosky et al. · 2013 [cited by applicant]
US 8496711B2 · Anapliotis et al. · 2013 [cited by applicant]
US 8500819B2 · Meridew et al. · 2013 [cited by applicant]
US 8529532B2 · Pinto et al. · 2013 [cited by applicant]
US 8579985B2 · Podolsky et al. · 2013 [cited by applicant]
US 8608802B2 · Bagga et al. · 2013 [cited by applicant]
US 8652216B2 · Chen et al. · 2014 [cited by applicant]
US 8673018B2 · Walls · 2014 [cited by applicant]
US 8685432B2 · Evans et al. · 2014 [cited by applicant]
US 8721520B2 · Caira et al. · 2014 [cited by applicant]
US 8974538B2 · Teeny et al. · 2015 [cited by applicant]
US 9173742B2 · Faccioli et al. · 2015 [cited by applicant]
US RE46283E · de Beaubien · 2017 [cited by applicant]
US 9707008B2 · Krebs et al. · 2017 [cited by applicant]
US 9795486B2 · Faccioli et al. · 2017 [cited by applicant]
US RE46669E · de Beaubien · 2018 [cited by applicant]
US 9925363B2 · Magagnoli · 2018 [cited by applicant]
US 10265182B2 · Foran · 2019 [cited by applicant]
US 10433965B2 · de Beaubien et al. · 2019 [cited by applicant]
US 10624794B2 · Sides et al. · 2020 [cited by applicant]
US 20010051831A1 · Subba Rao et al. · 2001 [cited by applicant]
US 20020143402A1 · Steinberg · 2002 [cited by applicant]
US 20020169507A1 · Malone · 2002 [cited by applicant]
US 20030060891A1 · Shah · 2003 [cited by applicant]
US 20030097184A1 · Mitsugi et al. · 2003 [cited by applicant]
US 20030187513A1 · Durniak · 2003 [cited by applicant]
US 20040036189A1 · Ensign et al. · 2004 [cited by applicant]
US 20040111162A1 · Southworth · 2004 [cited by applicant]
US 20040193268A1 · Hazebrouck · 2004 [cited by applicant]
US 20040193281A1 · Grimes · 2004 [cited by applicant]
US 20040225360A1 · Malone · 2004 [cited by applicant]
US 20050004680A1 · Saladino et al. · 2005 [cited by applicant]
US 20050021084A1 · Lu et al. · 2005 [cited by applicant]
US 20050107794A1 · Hazebrouck · 2005 [cited by applicant]
US 20050187555A1 · Biedermann et al. · 2005 [cited by applicant]
US 20050277936A1 · Siravo et al. · 2005 [cited by applicant]
US 20060004431A1 · Fuller et al. · 2006 [cited by applicant]
US 20060014120A1 · Sapian · 2006 [cited by applicant]
US 20060030945A1 · Wright · 2006 [cited by applicant]
US 20060093646A1 · Cima et al. · 2006 [cited by applicant]
US 20060121083A1 · Mor · 2006 [cited by applicant]
US 20070005142A1 · Rhodes et al. · 2007 [cited by applicant]
US 20070016163A1 · Santini et al. · 2007 [cited by applicant]
US 20070088442A1 · Cima et al. · 2007 [cited by applicant]
US 20070110804A1 · Royer · 2007 [cited by applicant]
US 20070123835A1 · Molander et al. · 2007 [cited by applicant]
US 20070179609A1 · Goble et al. · 2007 [cited by applicant]
US 20090069899A1 · Klein · 2009 [cited by applicant]
US 20090130167A1 · Shelton et al. · 2009 [cited by applicant]
US 20100042167A1 · Nebosky et al. · 2010 [cited by applicant]
US 20100042213A1 · Nebosky et al. · 2010 [cited by applicant]
US 20100042214A1 · Nebosky · 2010 [cited by examiner]
US 20100042215A1 · Stalcup et al. · 2010 [cited by applicant]
US 20100114324A1 · Gibbs et al. · 2010 [cited by applicant]
US 20100217401A1 · de Beaubien · 2010 [cited by applicant]
US 20100292803A1 · Giori · 2010 [cited by applicant]
US 20110015754A1 · Leonard · 2011 [cited by examiner]
US 20110208315A1 · Anapliotis et al. · 2011 [cited by applicant]
US 20110218644A1 · Meridew et al. · 2011 [cited by applicant]
US 20110236501A1 · Guelcher et al. · 2011 [cited by applicant]
US 20120109303A1 · Capote · 2012 [cited by applicant]
US 20130041472A1 · Rabiner et al. · 2013 [cited by applicant]
US 20130158595A1 · Mavani et al. · 2013 [cited by applicant]
US 20130209522A1 · Brooks et al. · 2013 [cited by applicant]
US 20130211334A1 · de Beaubien · 2013 [cited by applicant]
US 20130211369A1 · de Beaubien · 2013 [cited by applicant]
US 20130218100A1 · Armbruster et al. · 2013 [cited by applicant]
US 20130237908A1 · Clark · 2013 [cited by applicant]
US 20130289621A1 · Fulmer et al. · 2013 [cited by applicant]
US 20140194810A1 · Barsoum et al. · 2014 [cited by applicant]
US 20150038941A1 · Nebosky et al. · 2015 [cited by applicant]
US 20160199190A1 · Sharifi-Mehr et al. · 2016 [cited by applicant]
US 20160367371A1 · de Beaubien · 2016 [cited by examiner]
US 20170354507A1 · Foran · 2017 [cited by examiner]
US 20190290833A1 · Vogt et al. · 2019 [cited by applicant]
US 20190290834A1 · Vogt et al. · 2019 [cited by applicant]
US 20200038191A1 · de Beaubien et al. · 2020 [cited by applicant]
US 20200222196A1 · Vogt et al. · 2020 [cited by applicant]
US 20200323695A1 · Sides et al. · 2020 [cited by applicant]
US 20200330660A1 · Patel et al. · 2020 [cited by applicant]
US 20200330661A1 · Canner et al. · 2020 [cited by applicant]
US 20200360578A1 · Loske et al. · 2020 [cited by applicant]
US 20210069409A1 · Castleberry et al. · 2021 [cited by applicant]
US 20210085467A1 · Dietz et al. · 2021 [cited by applicant]
US 20210386942A1 · Brown et al. · 2021 [cited by applicant]
US 20220249238A1 · Link et al. · 2022 [cited by applicant]
CN 104168857A · 2014 [cited by applicant]
DE 3704089A1 · 1988 [cited by applicant]
DE 19722359A1 · 1998 [cited by applicant]
DE 19722389A1 · 1998 [cited by applicant]
DE 102010052914A1 · 2012 [cited by applicant]
EP 0692226A1 · 1996 [cited by applicant]
EP 2326287B1 · 2016 [cited by applicant]
IT VI20000025U1 · 2001 [cited by applicant]
JP 2005028129A · 2005 [cited by applicant]
JP 2012500056A · 2012 [cited by applicant]
JP 2014176714A · 2014 [cited by applicant]
KR 101377900B1 · 2014 [cited by applicant]
NZ 279442A · 1998 [cited by applicant]
WO WO03037166A2 · 2003 [cited by applicant]
WO WO2005006938A2 · 2005 [cited by applicant]
WO WO2007047420A2 · 2007 [cited by applicant]
WO WO2010019781A1 · 2010 [cited by applicant]
WO WO2010080667A1 · 2010 [cited by applicant]
WO WO2012030331A1 · 2012 [cited by applicant]
WO WO2013041906A1 · 2013 [cited by applicant]
WO WO2013059609A1 · 2013 [cited by applicant]
WO WO2019226805A1 · 2019 [cited by applicant]
Thabe, H. et al. (2007). “Two-stage Reimplantation with an Application Spacer and Combined with Delivery of Antibiotics in the Management of Prosthetic Joint Infection” Oper. Orthop Traumatol, 1:78-100. [German language… [cited by applicant]
Whiteside, L. et al. (2011). “Methicillin-resistant [cited by applicant]
Schwerdt, C. et al. (2021). “The bactericidal effect of vancomycin is not altered by tranexamic acid, adrenalin, dexamethasone, or lidocaine in vitro.” Scientific Reports, 11(1), 10739. 5 pages. https://doi.org/10.1038/… [cited by applicant]
Belay, E.S. et al. (2020). “Single-stage versus two-stage revision for shoulder periprosthetic joint infection: a systematic review and meta-analysis.” J Shoulder Elbow Surg, 29: p. 2476-2486. [cited by applicant]
Cancienne, J.M. et al. (2018). “Risk Factors for Repeat Debridement, Spacer Retention, Amputation, Arthrodesis, and Mortality After Removal of an Infected Total Knee Arthroplasty With Spacer Placement.” J Arthroplasty, … [cited by applicant]
Chung, A.S. et al. (2019). “Two-Stage Debridement With Prosthesis Retention for Acute Periprosthetic Joint Infections.” J Arthroplasty, 34(6): p. 1207-1213. [cited by applicant]
Cochran, A. et al. (2016). “Risk of Reinfection After Treatment of Infected Total Knee Arthroplasty.” J Arthroplasty, 31: p. S156-S161. [cited by applicant]
De Beaubien, B.C. et al. (2019). “Local Instillation of Vancomycin and Tobramycin Combined with Negative Pressure Wound Therapy During 7-Day Two-Stage Arthroplasty Improves Clinical Outcomes.” [Presentation slide]. AAOS… [cited by applicant]
Ekpo, T.E. et al. (2012, Sep. 22). “Abbreviated Two-Stage Exchange Arthroplasty for Periprosthetic Joint Infection: 2 to 6 Year Results.” [Poster presentation]. 31st Annual meeting of the European Bone and Joint Infecti… [cited by applicant]
Finsterbusch, A. et al. (1970). “Bone and joint perfusion with antibiotics in the treatment of experimental staphylococcal infection in rabbits.” J Bone Joint Surg Am, 52(7): p. 1424-1432. [cited by applicant]
Florschutz, A.V. et al. (2015). “Infection after primary anatomic versus primary reverse total shoulder arthroplasty.” J Shoulder Elbow Surg, 24(8): p. 1296-1301. [cited by applicant]
Kalbian, I., et al. (2020). “Culture-negative periprosthetic joint infection: prevalence, aetiology, evaluation, recommendations, and treatment.” Int Orthop, 44(7): p. 1255-1261. [cited by applicant]
Lescun, T.B. et al. (2000). “Continuous infusion of gentamicin into the tarsocrural joint of horses.” Am J Vet Res, 61(4): p. 407-412. [cited by applicant]
Lescun, T.B. et al. (2006). “Treatment with continuous intrasynovial antimicrobial infusion for septic synovitis in horses: 31 cases (2000-2003).” J Am Vet Med Assoc, 228(12): p. 1922- 1929. [cited by applicant]
Lloyd, K.C. et al. (1988). “Effect of gentamicin sulfate and sodium bicarbonate on the synovium of clinically normal equine antebrachiocarpal joints.” Am J Vet Res, 49(5): p. 650-657. [cited by applicant]
Lloyd, K.C., et al. (1988). “Plasma and synovial fluid concentrations of gentamicin in horses after intra-articular administration of buffered and unbuffered gentamicin.” Am J Vet Res, 49(5): p. 644-649. [cited by applicant]
Nelson, G.N. et al. (2016). “Outcomes in the treatment of periprosthetic joint infection after shoulder arthroplasty: a systematic review.” J Shoulder Elbow Surg, 25(8): p. 1337-1345. [cited by applicant]
Parvizi, J. et al. (2018). “The 2018 Definition of Periprosthetic Hip and Knee Infection: An Evidence-Based and Validated Criteria.” J Arthroplasty, 33(5): p. 1309-1314.e2. [cited by applicant]
Paxton, E.S. et al. (2019). “Periprosthetic Infections of the Shoulder: Diagnosis and Management.” J Am Acad Orthop Surg, 27(21): p. e935-e944. [cited by applicant]
Rabinowitz J. et al. (2020). “Utilization of Shoulder Arthroplasty in the United States—An Analysis of Current Trends and Future Predictions,” in MUSC Siegling Day Department of Orthopaedic Research Day 2020. Seminars i… [cited by applicant]
Schneider, R.K. et al. (1992). “Open drainage, intra-articular and systemic antibiotics in the treatment of septic arthritis/tenosynovitis in horses.” Equine Vet J, 24(6): p. 443-9. [Abstract: 2 pages]. [cited by applicant]
Shelly, M. et al. (2011). “Renal Toxicity Related to Antibiotic-Containing Orthopedic Cement.” Pharmacokinetics and Adverse Drug Reactions. 2 pages. [cited by applicant]
Ure, K.J. et al. (1998). “Direct-exchange arthroplasty for the treatment of infection after total hip replacement. An average ten-year follow-up.” J Bone Joint Surg Am, 80(7): p. 961-968. [cited by applicant]
Whitehair, K.J., et al. (1992). “Regional Limb Perfusion for Antibiotic Treatment of Experimentally Induced Septic Arthritis.” Vet Surg, 21(5): p. 367-73. [Abstract: 2 pages]. [cited by applicant]
Wroblewski, B.M. (1986). “One-stage Revision of Infected Cemented Total Hip Arthroplasty.” Clin Orthop Relat Res, (211): p. 103-107. [cited by applicant]
Zavala, J.A. et al. (2012). “Management of deep infection after reverse total shoulder arthroplasty: a case series.” J Shoulder Elbow Surg, 21(10): p. 1310-1315. [cited by applicant]
U.S. Appl. No. 16/513,599, filed Jul. 16, 2019, 2020-0038191. [cited by applicant]
U.S. Appl. No. 17/971,080, filed Oct. 21, 2022, US 20230041597. [cited by applicant]
PCT/US2024/16687, Feb. 21, 2024, WO 2024/178093. [cited by applicant]
PCT/US2024/16660, Feb. 21, 2024, WO 2024/178070. [cited by applicant]